z-logo
open-access-imgOpen Access
Requirement for Estrogen Receptor α in a Mouse Model for Human Papillomavirus–Associated Cervical Cancer
Author(s) -
Sang-Hyuk Chung,
Kerri Wiedmeyer,
Anny Shai,
Kenneth S. Korach,
Paul F. Lambert
Publication year - 2008
Publication title -
cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.103
H-Index - 449
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/0008-5472.can-08-2051
Subject(s) - estrogen , cervical cancer , estrogen receptor , carcinogenesis , cancer research , cancer , squamous metaplasia , estrogen receptor alpha , dysplasia , genetically modified mouse , biology , medicine , transgene , breast cancer , pathology , epithelium , genetics , gene
The majority of human cervical cancers are associated with the high-risk human papillomaviruses (HPV), which encode the potent E6 and E7 oncogenes. On prolonged treatment with physiologic levels of exogenous estrogen, K14E7 transgenic mice expressing HPV-16 E7 oncoprotein in their squamous epithelia succumb to uterine cervical cancer. Furthermore, prolonged withdrawal of exogenous estrogen results in complete or partial regression of tumors in this mouse model. In the current study, we investigated whether estrogen receptor alpha (ERalpha) is required for the development of cervical cancer in K14E7 transgenic mice. We show that exogenous estrogen fails to promote either dysplasia or cervical cancer in K14E7/ERalpha-/- mice despite the continued presence of the presumed cervical cancer precursor cell type, reserve cells, and evidence for E7 expression therein. We also observed that cervical cancers in our mouse models are strictly associated with atypical squamous metaplasia (ASM), which is believed to be the precursor for cervical cancer in women. Consistently, E7 and exogenous estrogen failed to promote ASM in the absence of ERalpha. We conclude that ERalpha plays a crucial role at an early stage of cervical carcinogenesis in this mouse model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here